CDSCO panel nod to Sun Pharma to study of anticancer drug Leuprolide acetate for depot suspension - Video
|
Overview
The drug major Sun Pharma has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the bioequivalence study of anticancer drug Leuprolide acetate depot suspension 7.5mg/vial (1 Month Depot), a man-made form of gonadotropin-releasing hormone (GnRH) that is used in men to treat the symptoms of prostate cancer.
This came after the drug major Sun Pharma presented bioequivalence study protocol No. C1B03530, Version No. 01 dated 18-Sep-2023.
For the full story, check out the link given below:
Sun Pharma Gets CDSCO Panel Nod To Study Leuprolide Acetate For Depot Suspension
Speakers
Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.